

# The Innovative Medicines Initiative (IMI)

---



## An Overview of the 2008 Call Topics


Jonathan Knowles

Chair, IMI Board


IMI Launch, April 30<sup>th</sup> 2008



# The Research Focus of IMI



# Efficacy and Safety are often disease specific



# IMI First Call: 18 Call Topics



- 5 on safety prediction
- 1 on pharmacovigilance
- 2 on diabetes
- 3 on brain disorders
- 2 on pulmonary diseases
- 5 on Education & Training

# Strong industry commitment



#	Title	Companies	In-kind (millions)
1	Improve Predictivity of Immunogenicity	12	€13
2	Non-genotoxic Carcinogenesis	8	€12,5
3	Expert Systems for in silico Toxicity Prediction	10	€5
4	Improved Predictivity of non-clinical Safety Evaluation	11	€10
5	Qualification of Translational Safety Biomarkers	12	€21
6	Strengthening the Monitoring of Benefit/Risk	15	€15
7	Islet Cell Research	11	€10
8	Surrogate Markers for Vascular Endpoints	7	€20
9	Pain Research	12	€7,5
10	New Tools for the Development of Novel Therapies in Psychiatric Disorders	13	€10
11	Neurodegenerative Disorders	14	€7,5
12	Understanding Severe Asthma	10	€12,5
13	COPD Patient Reported Outcomes	9	€10
14	European Medicines Research Training Network	24	€5
15	Safety Sciences for Medicines Training Programme	24	€3
16	Pharmaceutical Medicine Training Programme	24	€4
17	Integrated Medicines Development Programme	24	€3
18	Pharmacovigilance Training Programme	24	€3,5

# We cannot do it without the stakeholders

